{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:28:14Z","timestamp":1793852894695,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-04044-7","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:22Z","timestamp":1764138922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical outcomes after switching from omalizumab to anti-IL-5\/IL-5R biologics in severe asthma: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0519-7132","authenticated-orcid":false,"given":"Fatma Arzu","family":"Akku\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6595-1267","authenticated-orcid":false,"given":"Fatih","family":"\u00c7\u00f6lkesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-5925","authenticated-orcid":false,"given":"Tu\u011fba","family":"\u00d6nalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-0544","authenticated-orcid":false,"given":"Mehmet Emin","family":"Gerek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-6872","authenticated-orcid":false,"given":"Mehmet","family":"K\u0131l\u0131n\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0343-0159","authenticated-orcid":false,"given":"\u015eevket","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"1","key":"4044_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.alit.2022.11.008","volume":"72","author":"H Nagase","year":"2023","unstructured":"Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergology International: Official J Japanese Soc Allergology. 2023;72(1):11\u201323.","journal-title":"Allergology International: Official J Japanese Soc Allergology"},{"issue":"2","key":"4044_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/all.13966","volume":"75","author":"PJ McDowell","year":"2020","unstructured":"McDowell PJ, Heaney LG. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020;75(2):302\u201310.","journal-title":"Allergy"},{"key":"4044_CR3","doi-asserted-by":"publisher","first-page":"175346662092923","DOI":"10.1177\/1753466620929231","volume":"14","author":"GE Carpagnano","year":"2020","unstructured":"Carpagnano GE, Pelaia C, D\u2019Amato M, Crimi N, Scichilone N, Scioscia G, et al. Switching from Omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:1753466620929231.","journal-title":"Ther Adv Respir Dis"},{"key":"4044_CR4","doi-asserted-by":"publisher","first-page":"107414","DOI":"10.1016\/j.rmed.2023.107414","volume":"218","author":"L Rogers","year":"2023","unstructured":"Rogers L, Jesenak M, Bjermer L, Hanania NA, Seys SF, Diamant Z. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023;218:107414.","journal-title":"Respir Med"},{"key":"4044_CR5","doi-asserted-by":"publisher","first-page":"950883","DOI":"10.3389\/fmed.2022.950883","volume":"9","author":"C Caruso","year":"2022","unstructured":"Caruso C, Cameli P, Altieri E, Aliani M, Bracciale P, Brussino L, et al. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: an ANANKE study post hoc analysis. Front Med. 2022;9:950883.","journal-title":"Front Med"},{"key":"4044_CR6","doi-asserted-by":"publisher","unstructured":"Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6):1701782. https:\/\/doi.org\/10.1183\/13993003.01782-2017.","DOI":"10.1183\/13993003.01782-2017"},{"issue":"7","key":"4044_CR7","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","volume":"9","author":"J Bousquet","year":"2021","unstructured":"Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, et al. Real-World effectiveness of Omalizumab in severe allergic asthma: A Meta-Analysis of observational studies. J Allergy Clin Immunol Pract. 2021;9(7):2702\u201314.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"4044_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"issue":"1","key":"4044_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4104\/pcrj.2009.00010","volume":"18","author":"M Thomas","year":"2009","unstructured":"Thomas M, Kay S, Pike J, Williams A, Rosenzweig JR, Hillyer EV, et al. The asthma control test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respiratory Journal: J Gen Pract Airways Group. 2009;18(1):41\u20139.","journal-title":"Prim Care Respiratory Journal: J Gen Pract Airways Group"},{"key":"4044_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JAA.S328653","volume":"15","author":"AN Menzies-Gow","year":"2022","unstructured":"Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, Al-Ahmad M, Ambrose CS, et al. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. J Asthma Allergy. 2022;15:63\u201378.","journal-title":"J Asthma Allergy"},{"issue":"6","key":"4044_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000534319","volume":"32","author":"M Al-Ahmad","year":"2023","unstructured":"Al-Ahmad M, Ali A, Maher A. Omalizumab transitions in severe asthma: factors influencing switching decisions and timing for optimal response. Med Principles Practice: Int J Kuwait Univ Health Sci Centre. 2023;32(6):323\u201331.","journal-title":"Med Principles Practice: Int J Kuwait Univ Health Sci Centre"},{"key":"4044_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/JAA.S348513","volume":"15","author":"M Matsumoto-Sasaki","year":"2022","unstructured":"Matsumoto-Sasaki M, Simizu K, Suzuki M, Suzuki M, Kimura H, Nakamaru Y, et al. Clinical characteristics of patients and factors associated with switching biologics in asthma. J Asthma Allergy. 2022;15:187\u201395.","journal-title":"J Asthma Allergy"},{"issue":"3","key":"4044_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","volume":"195","author":"LC Denlinger","year":"2017","unstructured":"Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302\u201313.","journal-title":"Am J Respir Crit Care Med"},{"key":"4044_CR14","doi-asserted-by":"crossref","unstructured":"Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6(3):980-6.e1.","DOI":"10.1016\/j.jaip.2017.12.019"},{"issue":"9","key":"4044_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/all.12914","volume":"71","author":"A Magnan","year":"2016","unstructured":"Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous Omalizumab treatment. Allergy. 2016;71(9):1335\u201344.","journal-title":"Allergy"},{"issue":"12","key":"4044_CR16","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1111\/all.13937","volume":"74","author":"D Bagnasco","year":"2019","unstructured":"Bagnasco D, Menzella F, Caminati M, Caruso C, Guida G, Bonavia M, et al. Efficacy of mepolizumab in patients with previous Omalizumab treatment failure: Real-life observation. Allergy. 2019;74(12):2539\u201341.","journal-title":"Allergy"},{"issue":"1","key":"4044_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12931-021-01733-9","volume":"22","author":"MC Liu","year":"2021","unstructured":"Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, et al. Benefit of switching to mepolizumab from Omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res. 2021;22(1):144.","journal-title":"Respir Res"},{"key":"4044_CR18","doi-asserted-by":"publisher","unstructured":"Pelaia C, Crimi C, Nolasco S, Carpagnano GE, Brancaccio R, Buonamico E, et al. Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: a real-life experience from Southern Italy. Biomedicines. 2021;9(12):1822. https:\/\/doi.org\/10.3390\/biomedicines9121822.","DOI":"10.3390\/biomedicines9121822"},{"key":"4044_CR19","doi-asserted-by":"publisher","unstructured":"Pianigiani T, Paggi I, Cooper GE, Staples KJ, McDonnell M, Bergantini L. Natural killer cells in the lung: novel insight and future challenge in the airway diseases. ERJ Open Res. 2025;11(2):00683-2024. https:\/\/doi.org\/10.1183\/23120541.00683-2024.","DOI":"10.1183\/23120541.00683-2024"},{"key":"4044_CR20","doi-asserted-by":"publisher","first-page":"109680","DOI":"10.1016\/j.clim.2023.109680","volume":"253","author":"L Bergantini","year":"2023","unstructured":"Bergantini L, d\u2019Alessandro M, Pianigiani T, Cekorja B, Bargagli E, Cameli P. Benralizumab affects NK cell maturation and proliferation in severe asthmatic patients. Clin Immunol (Orlando Fla). 2023;253:109680.","journal-title":"Clin Immunol (Orlando Fla)"},{"issue":"9","key":"4044_CR21","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/all.13850","volume":"74","author":"KR Chapman","year":"2019","unstructured":"Chapman KR, Albers FC, Chipps B, Mu\u00f1oz X, Devouassoux G, Bergna M, et al. The clinical benefit of mepolizumab replacing Omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716\u201326.","journal-title":"Allergy"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-04044-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-04044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:06:11Z","timestamp":1767474371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-025-04044-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4044"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-04044-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was received for this study from the Ethics Committee of Necmettin Erbakan University, who approved this study protocol (2025\/5663). The study followed the guidelines and principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}